BlueWillow’s technology is broadly and narrowly protected by composition and method claims reflected in 20+ issued U.S. patents and 30+ issued international patents, as well as numerous pending CIP and new patent filings. The issued U.S. patents provide protection beyond 2030 for the company’s key intranasal vaccine candidates.

BlueWillow’s patent counsel is Foley & Lardner, LLP, located in Washington, DC.